| Literature DB >> 32104711 |
Minyi Tian1, Xianghuan Wu1, Yi Hong1, Huijuan Wang1, Guodong Deng1, Ying Zhou1,2.
Abstract
The chemical constituents and the antioxidant, antimicrobial, and cytotoxic activities of fresh rhizome essential oil (FR-EO) and dry rhizome essential oil (DR-EO) of Zingiber zerumbet (L.) Smith obtained from Southwest China were compared. Zerumbone was the predominant component in both FR-EO and DR-EO (75.0% and 41.9%, respectively). FR-EO, DR-EO, and zerumbone were all demonstrated to have significant antimicrobial capacity against Staphylococcus aureus, Bacillus subtilis, Escherichia coli, and Proteus vulgaris, with minimum inhibitory concentration (MIC) ranging from 31.25 to 156.25 μg/mL and minimum bactericidal concentration (MBC) ranging from 62.50 to 625.00 μg/mL. Zerumbone showed the strongest antimicrobial potential against all tested microorganisms compared with the fresh and dry rhizome essential oils. FR-EO was found to be more active than DR-EO against Staphylococcus aureus, Bacillus subtilis, Escherichia coli, and Proteus vulgaris. FR-EO, DR-EO, and zerumbone all showed significant cytotoxic activity against K562, PC-3, and A549 human tumor cell lines in a time- and concentration-dependent manner. Zerumbone exhibited the strongest antiproliferative activity against all tested human tumor cell lines with an IC50 of 4.21-11.09 μg/mL for 72 h incubation, as compared with the fresh and dry rhizome oils. The cytotoxic activity of FR-EO (IC50: 10.48-14.51 μg/mL for 72 h) was found to be significantly higher (p < 0.05) than that of DR-EO (IC50: 13.83-33.24 μg/mL for 72 h). FR-EO, DR-EO, and zerumbone exhibited selective cytotoxic activity to tumor cells, with a significantly low cytotoxicity to normal cells (MRC-5, IC50: 56.98-147.29 μg/mL). However, FR-EO, DR-EO, and zerumbone all exhibited weak free-radical-scavenging activity according to DPPH and ABTS analysis. The findings highlighted in this study show that FR-EO provides appreciably higher content of the bioactive compound, zerumbone, and has higher antimicrobial and cytotoxic properties than DR-EO. Thus, fresh Z. zerumbet rhizome should be preferred in cosmetic, food, and pharmaceutical applications.Entities:
Year: 2020 PMID: 32104711 PMCID: PMC7036102 DOI: 10.1155/2020/9641284
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Chemical composition of Z. zerumbet FR-EO and DR-EO.
| Compounda | RIb | RIc | % area | Identificationd | |
|---|---|---|---|---|---|
| DR-EO | FR-EO | ||||
| Tricyclene | 926 | 925 | 0.1 | 0.1 | MS, RI |
|
| 937 | 937 | 1.0 | 0.8 | MS, RI |
| Camphene | 952 | 952 | 3.9 | 3.3 | MS, RI |
| Sabinene | 976 | 974 | tr | tr | MS, RI |
|
| 980 | 979 | tr | tr | MS, RI |
|
| 992 | 991 | 0.1 | 0.1 | MS, RI |
|
| 1007 | 1005 | 0.1 | 0.1 | MS, RI |
|
| 1013 | 1011 | 0.5 | 0.2 | MS, RI |
|
| 1027 | 1023 | 0.1 | 0.1 | MS, RI |
| 1,8-Cineole | 1034 | 1032 | 1.6 | 1.2 | MS, RI |
|
| 1062 | 1060 | tr | tr | MS, RI |
| Fenchone | 1092 | 1096 | 0.1 | 0.1 | MS, RI |
| Linalool | 1101 | 1099 | 0.6 | 0.3 | MS, RI |
| Camphor | 1149 | 1145 | 2.4 | 1.3 | MS, RI |
| l-Borneol | 1170 | 1167 | 0.2 | 0.1 | MS, RI |
| 4-Terpineol | 1180 | 1182 | 0.1 | 0.1 | MS, RI |
|
| 1193 | 1189 | 0.2 | 0.1 | MS, RI |
| Verbenone | 1212 | 1204 | tr | tr | MS, RI |
| l-Bornyl acetate | 1291 | 1284 | 0.1 | tr | MS, RI |
| Isobornyl acetate | 1294 | 1286 | 0.1 | tr | MS, RI |
| Myrtenyl acetate | 1329 | 1327 | tr | tr | MS, RI |
|
| 1378 | 1376 | tr | tr | MS, RI |
|
| 1394 | 1391 | 0.1 | tr | MS, RI |
|
| 1417 | 1409 | 0.1 | tr | MS, RI |
|
| 1429 | 1419 | 2.5 | 0.4 | MS, RI |
|
| 1440 | 1435 | tr | tr | MS, RI |
|
| 1467 | 1454 | 29.4 | 6.5 | MS, RI |
|
| 1534 | 1524 | 0.1 | tr | MS, RI |
| Hedycaryol | 1560 | 1559 | 0.1 | tr | MS, RI |
|
| 1568 | 1564 | 0.1 | 0.1 | MS, RI |
| Caryophyllene oxide | 1599 | 1581 | 2.1 | 1.3 | MS, RI |
| Humulene oxide I | 1614 | 1596 | 6.0 | 3.8 | MS, RI |
| Humulene oxide II | 1625 | 1606 | 3.9 | 2.7 | MS, RI |
|
| 1657 | 1639 | 1.0 | 0.8 | MS, RI |
|
| 1663 | 1649 | 0.3 | 0.4 | MS, RI |
| Zerumbone | 1735 | 1732 | 41.9 | 75.0 | MS, RI |
| Monoterpene hydrocarbons (%) |
|
| |||
| Oxygenated monoterpenes (%) |
|
| |||
| Sesquiterpene hydrocarbons (%) |
|
| |||
| Oxygenated sesquiterpenes (%) |
|
| |||
| Total (%) |
|
| |||
| Yield (W/W) (%) |
|
| |||
aCompounds are listed in order of their elution from a HP-5MS column. bRetention index on the HP-5MS column, calculated using homologous series of C9–C18 alkanes. cRetention index from NIST 14 and Wiley 275 mass spectral databases. dIdentification: MS, based on comparison with Wiley 275 and NIST 14 MS databases; RI, based on comparison of calculated RI with those reported in Wiley 275 and NIST 14 databases. tr: trace (trace < 0.1%).
Figure 1GC-MS chromatogram of Z. zerumbet FR-EO.
Figure 2GC-MS chromatogram of Z. zerumbet DR-EO.
Antioxidant ability of FR-EO and DR-EO of Z. zerumbet and zerumbone.
| Sample | DPPH | ABTS | ||
|---|---|---|---|---|
| IC50 ( | AEAC (mg/100 g)b | IC50 ( | AEAC (mg/100 g)b | |
| DR-EO | 17416.04 ± 3274.95 | 9.01 | 2884.67 ± 232.71 | 74.90 |
| FR-EO | 32385.39 ± 5628.23 | 4.85 | 2926.68 ± 104.28 | 73.82 |
| Zerumbone | 90293.12 ± 3529.38 | 1.74 | 10840.13 ± 938.35 | 19.93 |
| BHTc | 29.25 ± 1.87 | 7.47 ± 0.12 | ||
| Ascorbic acidc | 1.57 ± 0.23 | 2.16 ± 0.43 | ||
aIC50: the concentration of sample that affords a 50% reduction in the assay, expressed as the means ± SD of triplicate experiments. bAEAC (ascorbic acid equivalent antioxidant capacity) = (IC50(AA)/IC50(Sample)) × 105. cBHT and ascorbic acid as positive control.
Diameter of the inhibition zones of Z. zerumbet FR-EO, DR-EO, and zerumbone using the agar disc diffusion method.
| Microorganisms | Diameter of the inhibition zones (mm)a | |||
|---|---|---|---|---|
| FR-EO | DR-EO | Zerumbone | Streptomycin | |
| Gram positive | ||||
| | 10.41 ± 2.31 | 9.31 ± 0.69 | 10.00 ± 0.68 | 9.74 ± 0.96 |
| | 14.54 ± 3.78 | 12.31 ± 1.22 | 15.72 ± 2.42 | 19.69 ± 1.63 |
| | 9.99 ± 1.86 | 8.55 ± 1.89 | 9.48 ± 1.96 | 9.38 ± 1.21 |
| Gram negative | ||||
| | 8.34 ± 0.70 | 8.23 ± 1.17 | 9.71 ± 0.97 | 8.36 ± 1.08 |
| | 9.36 ± 1.98 | 9.79 ± 1.68 | 10.85 ± 0.83 | 11.37 ± 0.88 |
| | 11.06 ± 1.01 | 10.29 ± 1.03 | 11.71 ± 1.55 | 17.13 ± 2.14 |
| Fungus | ||||
| | 10.93 ± 1.13 | 9.31 ± 1.80 | 11.31 ± 0.83 | Na |
aThe diameter of the inhibition zones (mm) were measured including the diameter of the disk (6 mm). The sample solution: FR-EO, DR-EO, and zerumbone were diluted with ethyl acetate, at a concentration of 100 mg/mL (tested volume: 20 μL); positive control: streptomycin (tested volume: 20 μL, 100 μg/mL).
MIC and MBC values of Z. zerumbet FR-EO, DR-EO, and zerumbone using microdilution assay.
| Microorganism | MIC and MBC ( | |||||||
|---|---|---|---|---|---|---|---|---|
| FR-EO | DR-EO | Zerumbone | Streptomycin | |||||
| MIC | MBC | MIC | MBC | MIC | MBC | MIC | MBC | |
| Gram positive | ||||||||
| | 1250.00 | 1250.00 | 1250.00 | 1250.00 | 250.00 | 250.00 | 0.20 | 0.78 |
| | 78.13 | 156.25 | 156.25 | 156.25 | 31.25 | 62.50 | 0.78 | 0.78 |
| | 78.13 | 156.25 | 156.25 | 312.50 | 62.50 | 125.00 | 0.10 | 0.20 |
| Gram negative | ||||||||
| | 312.50 | 625.00 | 312.50 | 625.00 | 250.00 | 250.00 | 3.13 | 12.50 |
| | 156.25 | 312.25 | 156.25 | 625.00 | 62.50 | 62.50 | 3.13 | 6.25 |
| | 78.13 | 156.25 | 156.25 | 312.50 | 62.50 | 62.50 | 0.20 | 0.39 |
| Fungus | ||||||||
| | 312.50 | 2500.00 | 312.50 | 2500.00 | 31.25 | 250.00 | Na | Na |
aMIC: minimal inhibitory concentration; MBC: minimal bactericidal concentration; streptomycin as positive control.
Cytotoxic properties of FR-EO and DR-EO of Z. zerumbet and zerumbone.
| Sample | Incubation time (h) | IC50 ( | |||
|---|---|---|---|---|---|
| A549b | PC-3c | K562d | MRC-5e | ||
| FR-EO | 24 | 44.88 ± 1.21 | 53.32 ± 1.34 | 35.73 ± 1.72 | 159.47 ± 9.34 |
| 48 | 38.64 ± 1.03 | 21.45 ± 1.18 | 13.73 ± 0.54 | 133.82 ± 5.97 | |
| 72 | 14.51 ± 0.61 | 11.23 ± 0.53 | 10.48 ± 0.95 | 106.21 ± 7.34 | |
|
| |||||
| DR-EO | 24 | 68.06 ± 1.09 | 77.45 ± 0.46 | 41.79 ± 1.18 | 216.99 ± 8.27 |
| 48 | 56.14 ± 1.76 | 43.90 ± 1.65 | 17.22 ± 0.51 | 164.68 ± 2.71 | |
| 72 | 33.24 ± 0.53 | 13.83 ± 0.59 | 14.96 ± 1.18 | 147.29 ± 4.30 | |
|
| |||||
| Zerumbone | 24 | 22.40 ± 1.80 | 30.78 ± 1.31 | 10.08 ± 0.61 | 117.96 ± 5.67 |
| 48 | 19.00 ± 0.72 | 14.30 ± 1.84 | 6.24 ± 1.05 | 79.79 ± 3.17 | |
| 72 | 11.09 ± 0.39 | 7.66 ± 0.68 | 4.21 ± 0.84 | 56.98 ± 1.82 | |
|
| |||||
| Cisplatinf | 24 | 5.17 ± 0.44 | 40.64 ± 1.38 | 20.36 ± 0.62 | 14.58 ± 0.91 |
| 48 | 3.38 ± 0.61 | 7.64 ± 0.39 | 11.53 ± 0.91 | 5.29 ± 0.67 | |
| 72 | 1.91 ± 0.87 | 2.16 ± 0.67 | 5.10 ± 0.54 | 2.99 ± 0.49 | |
aIC50: the sample concentration reduced cells growth by 50% (after 24-, 48-, and 72-hour incubation), expressed as the mean ± SD of triplicate experiments. bHuman lung cancer cell line. cHuman prostatic carcinoma cell line. dHuman leukemic cell line. eHuman fetal lung fibroblasts cell line. fCisplatin as positive control.